150sek
1,3 %
Date:2025-07-16Time:18:00:00Latest report:Q1-2025List:First NorthTicker:KAN
Market Cap:182 msekEnterprise Value:145 msekNet Sales:- msekEarnings:-44,5 msekEmployees:0ISIN:SE0015658570

Ratios

10-year key figure history for Kancera turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Kancera with index and moving average MA50 and MA200.

Stockprice:1,50
MA50:1,33
MA200:1,29
Price/MA200:16,5 %
RSI (14):52,5
Price/MA50:13,0 %

Description

Kancera is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Kancera is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.

Biotechnology